PACTR202209604592389尚未招募2 期
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •Patient has confirmed diagnosis of SCD
- •Documentation of SCD genotype (HbSS, HbSß0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing. Molecular genotyping is not required. SCD genotype may be determined from the results of Hb electrophoresis, high-performance liquid chromatography (HPLC), or similar testing. Note that Hb electrophoresis is performed by the local laboratory at Screening.
- •2. Hemoglobin = 5.5 and < 10.5 g/dL
- •3. Adolescent patients with severe SCD, as defined by at least 1 of the following:
- •Two or more VOCs in the past 12 months, defined as a previously documented episode of acute chest syndrome (ACS) or acute painful crisis (for which there was no explanation other than VOC) which required prescription or healthcare
- •professional-instructed use of analgesics for moderate to severe pain
- •Hospitalization for any SCD-related complication in the last 12 months
- •Proteinuria, defined as an albumin: creatinine ratio (ACR) > 100 mg/g on 2 measures (separated by = 1 month) as an indicator of early renal disease
- •History of a conditional TCD in the last 12 months, but not currently being treated with chronic transfusion therapy. Conditional TCD is defined as a TAMMV of 170-199 cm/s by TCD or 155-184 cm/s by imaging TCD (TCDi).
- •4. For participants taking HU, the dose of HU (mg/kg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the Investigator
- •5. Patients on crizanlizumab or L-glutamine treatment at the time of consent may be eligible if they:
- •Have been on a stable dose for = 12 months at the time of consent (ie, no changes to the dose except for changes to weight or for safety reasons)
- •For patients on crizanlizumab, have been = 80% compliant with the planned regimen during the 12 months prior to the time of consent
排除标准
- •Medical Conditions
- •1. More than 10 VOCs within the past 12 months that required a hospital, emergency room(ER), or clinic visit
- •2. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of Screening
- •3. Abnormal TCD in the prior 12 months
- •Prior/Concomitant Therapy
- •4. Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)
- •5. Received any blood products within 30 days of starting study treatment
- •6. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4/5 within 2 weeks of starting study treatment
- •7. Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study
- •8. Receipt of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study
- •9. Receipt of prior cellular based therapy (eg, hematopoietic cell transplant, gene modification therapy)
研究者
相似试验
尚未招募
1 期
Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell DiseaseHematology, Blood diseases, Sickle CellSickle Cell DiseaseLBCTR2022095118Forma Therapeutics, Inc.8
进行中（未招募）
不适用
Panitumumab in patients with neuroendocrine tumorWell differentiated neuroendocrine tumor (G1 and G2)MedDRA version: 14.1Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004539-22-ITI.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
招募中
2 期
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic MastocytosisNL-OMON55851Blueprint Medicines Corporation3
进行中（未招募）
1 期
A Study of Avapritinib in Patients with Advanced Systemic MastocytosisAdvanced Systemic Mastocytosis (AdvSM)MedDRA version: 20.0 Level: LLT Classification code 10056453 Term: Aggressive systemic mastocytosis System Organ Class: 100000004851EUCTR2017-004836-13-ESBlueprint Medicines Corporation60
进行中（未招募）
1 期
A Study of Avapritinib in Patients with Advanced Systemic MastocytosisAdvanced Systemic Mastocytosis (AdvSM)MedDRA version: 20.0Level: LLTClassification code 10056453Term: Aggressive systemic mastocytosisSystem Organ Class: 100000004864EUCTR2017-004836-13-ATBlueprint Medicines Corporation103